[EN] SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE DE TYPE SPIROPYRROLIDINE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
申请人:MERCK SHARP & DOHME
公开号:WO2010094242A1
公开(公告)日:2010-08-26
The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
Ketoximes to N-substituted thioamides via PSCl3 mediated Beckmann rearrangement
作者:Uma Pathak、Lokesh Kumar Pandey、Sweta Mathur、M. V. S. Suryanarayana
DOI:10.1039/b911844f
日期:——
N-Substituted thioamides were accessed from ketoximes by utilising PSCl3 as a uniquely capable reagent to induce Beckmannrearrangement as well as to capture the intermediate nitrilium ion.
Efficienttransamidation of unactivated carboxamides, phthalimides, formamides and thioamides with amines undersolvent-freeconditions using H-β-zeolite as a green and recyclable heterogeneous catalyst is described. Easy work up, high purity of the products, recyclability and environmentally-friendly nature of the catalyst are the attractive features of the present methodology. This is the first report